Studies reported cereblon (CRBN) as one of the E3 ligase other than VHL E3 ligase, which is commonly expressed in various cancer cell types but less in platelets.[40] This information led researchers to develop CRBN E3 ligase‐based PROTACs to reduce the on‐target platelet toxicity of Bcl‐xL inhibitors. The gene discussed is CRBN; the disease is cancer.